(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual revenue growth rate of 29.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.72%, and while it is forecast to beat the US market's average forecast revenue growth rate of 16.14%.
Vanda Pharmaceuticals's revenue in 2026 is $216,105,000.On average, 7 Wall Street analysts forecast VNDA's revenue for 2026 to be $15,501,080,868, with the lowest VNDA revenue forecast at $14,481,467,350, and the highest VNDA revenue forecast at $16,620,586,956. On average, 7 Wall Street analysts forecast VNDA's revenue for 2027 to be $21,298,987,530, with the lowest VNDA revenue forecast at $18,883,833,424, and the highest VNDA revenue forecast at $24,986,737,522.
In 2028, VNDA is forecast to generate $27,064,384,776 in revenue, with the lowest revenue forecast at $23,402,051,238 and the highest revenue forecast at $32,446,761,988.